An observational, prospective study investigating the efficacy of switch to a dual regimen of raltegravir plus darunavir/ritonavir in patients with HIV-1 infections on stable combination antiretroviral therapy

Trial Profile

An observational, prospective study investigating the efficacy of switch to a dual regimen of raltegravir plus darunavir/ritonavir in patients with HIV-1 infections on stable combination antiretroviral therapy

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Feb 2016

At a glance

  • Drugs Darunavir/ritonavir (Primary) ; Raltegravir (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Feb 2016 New trial record
    • 05 Jan 2016 Results were published in HIV Clinical Trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top